medicament$47518$ - traducción al griego
Diclib.com
Diccionario ChatGPT
Ingrese una palabra o frase en cualquier idioma 👆
Idioma:

Traducción y análisis de palabras por inteligencia artificial ChatGPT

En esta página puede obtener un análisis detallado de una palabra o frase, producido utilizando la mejor tecnología de inteligencia artificial hasta la fecha:

  • cómo se usa la palabra
  • frecuencia de uso
  • se utiliza con más frecuencia en el habla oral o escrita
  • opciones de traducción
  • ejemplos de uso (varias frases con traducción)
  • etimología

medicament$47518$ - traducción al griego

FRENCH PHARMACEUTICALS AND HEALTH CARE PRODUCTS COMPANY
Pierre Fabre Group; Pierre Fabre Medicament

medicament      
n. φάρμακο

Definición

Pharmaceutical
·adj Of or pertaining to the knowledge or art of pharmacy, or to the art of preparing medicines according to the rules or formulas of pharmacy; as, pharmaceutical preparations.

Wikipedia

Laboratoires Pierre Fabre

Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company. The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international). It is headquartered in the city of Castres, Midi-Pyrénées, France.

Founded in 1962 by Pierre Fabre (1926-2013), the company is present in over 130 countries. Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France. The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. Pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover).

Pierre Fabre is best known for its vinorelbine (Navelbine), an anticancer drug of the vinca alkaloid class. They also developed vinflunine, a fluorinated vinca alkaloid derivative available in Australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen."

Olivier Bohuon was Chief Executive from September 2010 to April 2011.